digital health regulation
The agency's proposal would classify the majority of software released by pharmas as "promotional labeling" that would not require premarket review.
The results to our poll about the FDA program prompt questions about the program's fairness to companies big and small.
The agency has reinvented the process for clearing digital health products but reviews are mixed.